Patent ID: 7022337
Filing Date: 2006-04-04
Classification: A61K,Y02A

Abstract:
1. A method of treating an endogenous condition selected from the group consisting of hyperlipidaemias, hypercholesterolaemias and hypertriglyceridaemias in a mammal comprising the administration of an oral self-emulsifying pharmaceutical formulation of a fibrate with improved oral bioavailability, wherein said formulation consists essentially of a fibrate dissolved in at least one fibrate solubilizer, at least one surfactant and at least one stabilizer, wherein said fibrate is selected from the group consisting of fenofibrate, derivative of fenofibrate and mixtures thereof, wherein said at least one fibrate solubilizer is selected from the group consisting of an N-alkyl derivative of 2-pyrrolidone, monoethylene glycol monoethers, diethylene glycol monoethers, higher-ethylene glycol monoethers, polyethylene glycol monoethers, C wherein said at least one or more surfactant is selected from the group consisting of nonionic, anionic, cationic, and zwitterionic surfactants and combinations thereof; wherein the fibrate to the fibrate solubilizer weight ratio is between about 1:1 and about 1:16, and wherein said at least one stabilizer is present in an amount sufficient to prevent the crystal growth of the fibrate, wherein fibrate remains in solution in said formulation and no crystallization of fibrate is observed for at least 24 hours, wherein the amount of said solubilizer is between about 20% to about 80% by weight of the formulation, and wherein the amount of said stabilizer is up to about 30% by weight of the formulation.